TELO
Telomir Pharmaceuticals, Inc. Common Stock
Mentions (24Hr)
133.33% Today
Reddit Posts
Mentions
Got on the TELO train and let us see how this goes..
guys anyone bought TELO? I think it's gonna shoot up
I believe TELO is showing us what IXHL will be able to do. Absolutely launched!!!
Either the TELO trade is just beginning or it's over, not sure.
Guys..get on TELO. Huge upside with new drug news. already up over 100% pre-market.
What happened with TELO up 140 percent after hours
https://ir.telomirpharma.com/telomir-pharmaceuticals-prevents-cellular-aging-in-patient-derived-cells-from-children-with-progeria-an-ultra-rare-genetic-disorder-that-causes-rapid-aging/ Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging - Telomir Pharmaceuticals, Inc. (TELO)
Telomir moving aftermarket after good phase-I data. $TELO
Check out this video: [https://www.mysuncoast.com/2024/08/16/abc7-exclusive-new-study-reveals-promising-results-age-reversal-pill-dogs/](https://www.mysuncoast.com/2024/08/16/abc7-exclusive-new-study-reveals-promising-results-age-reversal-pill-dogs/) Stock: $TELO (hit a low price today) An early stage company (see slide#25): [https://ir.telomirpharma.com/pechoagl/2025/06/Telomir-Full-Deck.pdf](https://ir.telomirpharma.com/pechoagl/2025/06/Telomir-Full-Deck.pdf) They continue to show progress: [https://ir.telomirpharma.com/press-releases/](https://ir.telomirpharma.com/press-releases/) It is a long shot but this could be a **100-bagger** in 2-5 years because if their longevity pill works, their market is all the humans and pets on the planet
* 100x TELO * 10x BBAI * 4x WRD * 3x PONY * 2x ACHR * 2x SOFI
Telomir Pharmaceuticals (TELO) today announced compelling preclinical results from a study evaluating its novel oral therapeutic, Telomir-1, in a genetically modified zebrafish model of age-related macular degeneration (AMD). Following a 14-day oral dosing regimen, Telomir-1 reversed central vision response and vision acuity, restored retinal degeneration and architecture, and significantly reduced oxidative stress—achieving improvements across several FDA-recognized surrogate endpoints relevant to AMD. The study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which combines genetic mutations associated with premature aging (WRN), mitochondrial dysfunction (ND6), and chronic senescence (Sen57). These animals exhibit progressive retinal degeneration, visual impairment, and oxidative stress—closely modeling dry AMD and geographic atrophy in humans.
TELO - Longevity treatment
Telomir Pharmaceuticals TELO today announced it has secured $3 million in equity financing, through a direct investment by The Bayshore Trust, the Company’s largest shareholder. The transaction involved the purchase of 1 million restricted shares of the Company’s common stock at $3.00 per share, representing an 18% premium to Telomir’s closing share price of $2.54 on the date of execution. The transaction was structured as a straight restricted common stock transaction with no warrants, no discounts, and no convertible features.
Telomir Pharmaceuticals (TELO) continues to expand its potential portfolio and just announced that it had identified Telomir-Ag2 as a novel drug candidate for the treatment of bacterial infections. According to the company, Telomir-Ag2 is a stabilized Silver(II) complex that, in preclinical testing, showed broad-spectrum antimicrobial activity, including against MARSA (methicillin- and aminoglycoside-resistant *Staphylococcus aureus).* According to the CDC, MARSA is a drug-resistant variant responsible for infections in hospitals and in the US causes over 323,000 hospitalizations and more than 10,000 deaths per year. According to Verified Market Research the silver wound dressing market is expected to reach $1.36 billion by 2030, while the antimicrobial coatings market is expected to reach $33.7 billion by 2031.
Telomir Pharmaceuticals (TELO) today announced the identification of Telomir-Ag2 as a novel drug candidate for the treatment of bacterial infections, including those caused by drug-resistant pathogens. This follows Telomir’s recent breakthrough in stabilizing Silver(II) in a biologically compatible form using its proprietary Telomir-1 platform. Telomir-Ag2 is a stabilized Silver(II) complex that demonstrated broad-spectrum antimicrobial activity in preclinical studies, including against methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA), one of the most challenging pathogens in clinical settings. “In the lab, Silver(II) has always shown remarkable antimicrobial potential, but it was considered too unstable for real-world use,” said Erez Aminov, CEO and Chairman of Telomir.
Update on Telomir Pharma (TELO): On Thursday, Rodman & Renshaw initiated coverage on Telomir Pharma shares, issuing a Buy rating with a price target of $15.00. The firm's valuation is based on a detailed analysis of the company's financial prospects and the potential of its Wilson's disease program. The assessment by Rodman & Renshaw estimates a net present value (NPV) of approximately $300 million for the Wilson's disease program, which translates to around $9 per share. This valuation takes into account a 30% probability adjustment and a 21% tax rate, extending through to 2044 and using a 15% discount rate. In addition to the Wilson's disease program, Rodman & Renshaw has recognized the inherent technology value of Telomir-1, the company's leading drug candidate. The technology value is appraised at $200 million, or $6 per share, reflecting the drug's potential for treating additional indications beyond Wilson's disease.
news on TELO [https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/telomir-pharmaceuticals-announces-significant-reduction-of-oxidative-s-986790](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/telomir-pharmaceuticals-announces-significant-reduction-of-oxidative-s-986790)
Start doing research on peptides and longevity companies. Here is the purest longevity play - Telomir Pharmaceuticals (NASDAQ: TELO)
Kennedy is confirmed as new Health Minister. Start doing research on peptides and longevity plays. Here is the purest longevity play - Telomir Pharmaceuticals (NASDAQ: TELO)
IPWR - cleanest small cap semiconductor TELO - best to play longevity MIRA - cleanest ketamin play ACOG - one of the cheapest commercial stage Alzheimer's name KULR - with the new bitcoin investments it became interesting IINN - small cap Medtech name. It solves a major issue PERF - super cheap beauty tech AI name, cash flow + net income positive, $157M cash on hand
TELO currently down from that high...
TELO up 12% pre-market Telomir Pharmaceuticals (TELO) announced preclinical findings showing Telomir-1 fully reverses oxidative stress caused by copper-induced Reactive Oxygen Species (ROS) in human cell lines. Oxidative stress contributes to aging, Alzheimer’s, AMD, cancer, and viral infections like avian influenza (bird flu). Telomir-1 demonstrated the ability to normalize ROS, protect cells from copper toxicity, and function effectively at low doses. Its potential spans treatments for Wilson’s disease, Alzheimer’s, and cardiovascular conditions, offering a novel approach to reduce cellular damage.
Telomir Pharmaceuticals $TELO Expands Focus to Wilson’s Disease Telomir Pharmaceuticals $TELO has announced groundbreaking preclinical findings demonstrating Telomir-1’s strong copper-binding capabilities. This positions the compound as a promising candidate for treating Wilson’s disease, a rare genetic disorder causing toxic copper accumulation in vital organs. Preclinical studies conducted by Recipharm and Smart Assays revealed Telomir-1’s ability to selectively bind copper, iron, and zinc, offering a novel therapeutic approach to copper regulation. Current treatments for Wilson’s disease often involve significant side effects and lifelong adherence, underscoring the urgent need for safer, more effective alternatives. With plans to initiate IND-enabling studies in 2025, Telomir is poised to advance Telomir-1’s development for human and veterinary applications. [https://www.accesswire.com/958618/telomir-pharmaceuticals-confirms-copper-binding-capabilities-of-telomir-1-and-expands-pipeline-into-wilsons-disease](https://www.accesswire.com/958618/telomir-pharmaceuticals-confirms-copper-binding-capabilities-of-telomir-1-and-expands-pipeline-into-wilsons-disease)
for IPWR [https://imgur.com/a/fSFzcc8](https://imgur.com/a/fSFzcc8) for TELO [https://imgur.com/a/jzUfWMx](https://imgur.com/a/jzUfWMx) for MIRA [https://imgur.com/tBKlEm3](https://imgur.com/tBKlEm3)
Check out $TELO $MIRA $PROF I love them
**Telomir Pharmaceuticals $TELO Secures $1 Million Equity Investment at Premium Price** Telomir Pharmaceuticals $TELO has strengthened its financial position by issuing 142,857 shares of common stock to an accredited investor at $7 per share, raising $1 million. The transaction, completed on December 9, 2024, represents a 20% premium to the company’s market price, signaling strong investor confidence in its innovative pipeline and strategic direction. This funding builds on a $5 million non-dilutive line of credit extended earlier this year by the same investor, which remains undrawn. Together, these financial moves underscore Telomir’s ability to secure favorable terms while advancing its mission to develop therapies targeting age-related and chronic conditions. The premium pricing highlights the market’s recognition of Telomir’s growth potential and strategic vision, positioning the company to continue pursuing breakthroughs in healthcare.
> $TELO is the future for longevity Great news interesting
$TELO is the future for longevity Great news recently
# Telomir Pharmaceuticals Surges 22% Following Breakthrough Diabetes Study **$TELO** saw its stock jump 22% today after announcing groundbreaking preclinical results for its investigational therapy, Telomir-1, targeting Type 2 diabetes. The study revealed Telomir-1’s ability to reverse key diabetes parameters, including reductions in fasting plasma glucose to basal levels, improved glucose homeostasis, and near-normal insulin sensitivity. The findings, supported by significantly improved HOMA-IR values, underscore the drug’s potential to address the disease’s root causes rather than merely managing symptoms. These promising results come as Type 2 diabetes affects over 800 million adults globally, costing healthcare systems more than $966 billion annually. Existing therapies often focus on symptom management and have notable side effects, including cardiovascular risks and weight gain. Telomir-1’s dual focus on reversing insulin resistance and enhancing survival rates positions it as a potential game-changer in diabetes treatment, driving strong investor optimism.
I caught $PROF $TELO $MIRA $KULR $IPWR **$TELO** \- Earlier co announced groundbreaking preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus **$PROF** \- their FDA approved prostate cancer product is ramping up sales on the market. It is available in Asia, Western-Europe and US. Currently, 50 US hospitals using the treatment. Patient and doctor feedback is great. Projects $26M in revenues next year. **$MIRA** \- continues to make significant progress in its broader pipeline. Preclinical studies for diabetic neuropathy and PTSD are ongoing, and the Company remains on track to complete its IND submission by year-end. Capsule manufacturing for the Phase I/IIa trial is also in its final stages, ensuring readiness for patient dosing in early 2025. **$IPWR** \- Ideal Power announced that the company secured a multi-unit order for its SymCool IQ intelligent power module from a customer that specializes in the development and manufacture of circuit protection and power conversion solutions. The customer previously ordered multiple SymCool power modules and drivers. **$KULR** \- co went through a big corporate restructuring. They decreased corporate spending from $6M to $1.5M/quarter. Co announced a new deal with NASA earlier and keep ramping up more & more contracts. Co should do well in 2025.
$TELO shares are up 20% after the co announced pre-clinical results confirming the efficacy of its licensed molecule in reversing in reversing parameters of type 2 diabetes Mellitus. These results highlight Telomir-1’s novel approach, targeting iron metabolism to reduce oxidative stress and beta-cell damage—root causes of insulin resistance. Current diabetes treatments primarily manage symptoms, but Telomir-1's ability to reverse underlying mechanisms offers transformative possibilities.
Check out $PROF $MIRA $TELO $IPWR
**Telomir Pharmaceuticals Reports Breakthrough in Type 2 Diabetes Study with Telomir-1** Telomir Pharmaceuticals $TELO has announced preclinical findings showcasing Telomir-1's groundbreaking potential in addressing Type 2 diabetes. Conducted on zebrafish models, the study demonstrated significant improvements in glucose regulation, including normalized fasting glucose levels and enhanced insulin sensitivity, reducing resistance to near pre-diabetic levels. These results highlight Telomir-1’s novel approach, targeting iron metabolism to reduce oxidative stress and beta-cell damage—root causes of insulin resistance. Current diabetes treatments primarily manage symptoms, but Telomir-1's ability to reverse underlying mechanisms offers transformative possibilities.
TELO. A company with a chemical that can increase telomere length in dogs.